Overcoming antigen tolerance to develop GB22–45-2, an anti-DKK1 antibody for gastric cancerWenjun Zhang(ZTE (China)), Suofu Qin(Drug Discovery Laboratory (Norway))Antibody TherapeuticsOctober 1, 202510.1093/abt/tbaf024Cited by 0SaveCiteExport RISWatch citationsRelated PapersKinetic Profiling of Oxidoreductase-Mimicking Nanozymes: Impact of Multiple Activities, Chemical Transformations, and Colloidal Stability|ACS Nano|2024|37